EUVIMEDEUVIMED entdecken
Crossref

PDL1 Monoclonal Antibody-Modified mPEG–PLGA-NH 2 Nanocomposite Loaded with Heterophyllin B for the Treatment of Gastric Cancer

Yunhai Wei iD, Wenjing Hu, Huancen Guo, Jinyu Zhang, Jingrui Cao, Chu Shen, Zhongxin Wu, Lei Yin, Yuhai Gao

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yunhai Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University; Huzhou Cen…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Polyethylene Glycols, B7-H1 Antigen, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, Zhejiang Province Public Welfare Technology Application Research Project, Zhejiang Chinese Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) show effectiveness in gastric cancer (GC) treatment, yet enhancing their efficacy remains challenging. We encapsulated the anticancer compound Heterophyllin B (HB) in mPEG-PLGA-NH2 nanoparticles (NPs), modified with αPDL1, forming mPEG-PLGA-NH2@HB-αPDL1 NPs. These NPs displayed low toxicity to GES-1 cells and good blood compatibility. They effectively inhibited GC cell malignant phenotypes and downregulated PD-L1 expression via the PI3K/AKT pathway. In GC allograft mice, the HB and αPDL1 combination therapy outperformed monotherapy, with the NPs showing better efficacy than free drugs. Additionally, the NPs improved the tumor immune microenvironment. H&E staining confirmed no significant toxicity to major mouse organs. Thus, mPEG-PLGA-NH2@HB-αPDL1 offers a promising strategy for optimizing ICI therapy in GC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsPolyethylene GlycolsB7-H1 AntigenAntibodies, MonoclonalAntineoplastic AgentsAnimalsHumansMiceCell Line, TumorNanoparticlesMice, Inbred BALB CDrug CarriersPolyesters

Substanzen

Polyethylene GlycolsB7-H1 AntigenAntibodies, MonoclonalCD274 protein, humanAntineoplastic AgentsDrug Carriersmethoxypolyethyleneglycol-poly(lactic-co-glycolic acid)Polyesters

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University; Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzho…
  • Department of Gastrointestinal Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou 313000, China.

ORCID-Profile: Yunhai Wei

Förderung

  • Medical Science and Technology Project of Zhejiang Province
  • Zhejiang Province Public Welfare Technology Application Research Project
  • Zhejiang Chinese Medical University

Zitieren

APA

Wei, Y., Hu, W., Guo, H., Zhang, J., Cao, J., Shen, C., Wu, Z., Yin, L., & Gao, Y. (2025). PDL1 Monoclonal Antibody-Modified mPEG–PLGA-NH 2 Nanocomposite Loaded with Heterophyllin B for the Treatment of Gastric Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01343

Vancouver

Wei Y, Hu W, Guo H, Zhang J, Cao J, Shen C, et al. PDL1 Monoclonal Antibody-Modified mPEG–PLGA-NH 2 Nanocomposite Loaded with Heterophyllin B for the Treatment of Gastric Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01343

BibTeX
@article{Wei2025,
  author = {Wei, Yunhai and Hu, Wenjing and Guo, Huancen and Zhang, Jinyu and Cao, Jingrui and Shen, Chu and Wu, Zhongxin and Yin, Lei and Gao, Yuhai},
  title = {PDL1 Monoclonal Antibody-Modified mPEG–PLGA-NH 2 Nanocomposite Loaded with Heterophyllin B for the Treatment of Gastric Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01343}
}
Kostenlos starten →